Monday, March 15, 2021

Get the infection, take the medicine, get over it and get durable immunity to variants. Not so for the poor vaccinated population, whose immunity against variants is poor/ Cell journal


  • Numerous variants of SARS-CoV-2 harboring mutations in spike have arisen globally
  • mRNA vaccines elicit potent neutralizing activity against homologous pseudovirus
  • Cross-neutralization of strains with receptor binding domain (RBD) mutations is poor
  • Both RBD and non-RBD mutations mediate escape from vaccine-induced humoral immunity
  • Summary
  • Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.


Julian said...

“...broadly protective interventions...”? Such as ivermectin?

Meryl Nass, M.D. said...

Ivermectin seems to be the most potent. But there are at lest a dozen medications and OTC proucts that appear to have some efficacy. Keep Vit D level up and zinc; that seems to be preventive of severe disease.

One can do the Latin American approach: take these 5 drugs when sick, or be judicious, basing treatment on symptoms and where you are chronologically in the illness.

Anonymous said...

One Sentence Summary Three mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma.

Competing Interest Statement

Rino Rappuoli is an employee of GSK group of companies. Emanuele Andreano, Ida Paciello, Elisa Pantano, Noemi Manganaro and Rino Rappuoli are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications n. 102020000015754 filed on June 30th 2020 and 102020000018955 filed on August 3rd 2020.

Meryl Nass, M.D. said...

Not only is Rino an employee of GSK, he is probably their top vaccine scientist. I have followed him for 20 years, from Chiron to Novartis to GSK. He is very intelligent. This paper is imo probably vaccine marketing.